Form 4 KALOBIOS PHARMACEUTICALS For: Nov 18 Filed by: Anthion Partners II LLC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
KaloBios Pharma (KBIO) Receives NASDAQ Delisting Notice
November 23, 2015 5:46 PM ESTThe NASDAQ Stock Market notified KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), by letter dated November 17, 2015, that the Company is not currently in compliance with Nasdaqs continued listing requirement set forth in Rule 5250(c)(1) of the Nasdaq Listing Rules (the Rules), due to its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 (the 2015 Third Quarter 10-Q) with the Securities and Exchange Commission (the SEC).
Under the Rules, the Company has 60 calendar days from November 17, 2015 to submit a plan to Nasdaq to regain compliance with the Rules. The Company intends to file... More
